Understanding immune responses to a shingles vaccine in patients with kidney disease
Official title: PERSISTENCE OF IMMUNE RESPONSES TO THE RECOMBINANT ZOSTER VACCINE IN IMMUNE COMPROMISED HOSTS WITH END-STAGE RENAL DISEASE WITH AND WITHOUT KIDNEY TRANSPLANTATION
Funded at University of Colorado Denver · NIH-11014039 · Data updated 2026-11-12
This study is looking at how well the shingles vaccine works for people with severe kidney disease or those who have had a kidney transplant, to see if extra doses can help boost their protection against infections.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | March 6, 2019 |
| Project end | February 28, 2029 |
| Funding year | 2025 |
| Award (this year) | $765,085 |
| NIH project number | 5U01AI141919-07 |
| Project ID | NIH-11014039 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates include adults with end-stage renal disease or those who have undergone kidney transplantation.
✕Less likely to help
Patients who are healthy and do not have any immunocompromising conditions may not benefit from this research.
What this research studies
This research investigates how well the recombinant zoster vaccine (RZV) works in individuals with end-stage renal disease (ESRD) and those who have received kidney transplants. It aims to identify the immune responses and metabolic factors that affect the vaccine's effectiveness in these immunocompromised patients. Participants will receive the vaccine and be monitored over time to assess their immune responses compared to healthy adults. The study will help determine if additional doses of the vaccine improve protection against infections.
Why it matters
Potential benefit: If successful, this research could enhance vaccination strategies for immunocompromised patients, improving their protection against severe infections.
How similar studies have gone: Previous research has shown that the recombinant zoster vaccine is effective in healthy adults, but its effectiveness in immunocompromised populations is less understood, making this research both relevant and necessary.
Where this research is happening
-
University of Colorado Denver
Aurora, United States Active
Researchers
- Principal investigator: Weinberg, Adriana — University of Colorado Denver
- Study coordinator: Weinberg, Adriana
Related research
Other NIH-funded projects on the same topics.
-
How long the shingles (zoster) vaccine protects people with kidney failure, before and after transplant
This project checks how long the shingles vaccine protects adults with end-stage kidney disease who are waiting for or have received a kidney transplant.
-
Strategies for HIV-to-HIV kidney transplants to increase organ donations
This project looks at making HIV-to-HIV kidney transplantation more common to help people with HIV get transplants faster by boosting organ donation and changing practice.
-
Biomarker-guided Immunosuppression in Kidney Transplant Patients
A multicenter study in kidney transplant recipients is testing whether a biomarker score from HLA-DR/DQ can guide changes in immunosuppression to reduce rejection risk and drug toxicity.
-
Helping the immune system accept a donated kidney in patients without prior sensitization
This project will try giving specially treated donor B cells alongside immune-sparing medicines to teach the immune systems of kidney transplant patients without prior antibodies to accept the new kidney.
-
Lowering donor-specific antibodies in sensitized kidney transplant patients
This project works to reduce harmful donor-specific antibodies in people who are sensitized and need a kidney transplant so their new organ lasts longer.
-
How life circumstances affect brain aging in people with end-stage kidney disease
This project looks at how neighborhood, income, education, and personal resilience relate to earlier memory and thinking problems in adults with end-stage kidney disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.